Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
about
The Evolution of Therapies in Non-Small Cell Lung CancerTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerLet-7 Sensitizes KRAS Mutant Tumor Cells to ChemotherapyA label-free mass spectrometry method for relative quantitation of β-tubulin isotype expression in human tumor tissue.P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsTubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cellsUbc9 expression predicts chemoresistance in breast cancer.Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerQuantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerSynthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistanceβV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerRationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expressionSynthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.Mechanisms of resistance to cabazitaxel.Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapyExpressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or CisplatinMicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents.Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signaturesDesign, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.High expression of class III β-tubulin in small cell lung carcinoma.Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer.[The molecular markers related to personalized therapy of non-small cell lung cancer].
P2860
Q26786932-0D96AD52-6E49-45DF-845D-FF36E103033EQ28396304-8C8AC6A0-8049-4DB3-9917-B0B1FD77057BQ28547017-6D4B64EE-5BA5-4A61-8C77-BCE509E30898Q31097343-1D6C7EEE-4D22-4739-BF43-1F863D7851FEQ33472987-7DBB2C8C-0BC5-46B4-84B5-7AFB57989075Q33552792-630A00F9-2E2D-44F3-A443-57DED122F86FQ33579371-2A3DA042-0D12-4A43-9AEF-F2D5357A84A7Q33589802-0893C29E-75A4-4779-9E7C-585F4CA161AAQ33914197-E2627E4A-A5A3-4C9E-A410-49E142D71C16Q34243429-B4B1CD8C-839D-412D-AD72-646577169B71Q34336551-54856EE9-2EFA-41D6-8635-62A09C0E251AQ34353248-7E185D34-CD65-41A5-A05F-89D9F419CCBCQ34360044-0A8FE86A-0FB8-484E-B8F2-486B6D9143E4Q34988593-04713342-20A3-4142-9AB4-4029696B7228Q35110635-7813953C-F096-4946-945A-37449B8005F9Q35140489-D582516C-7F24-4E05-8CD4-784CD214E470Q35154831-86C59773-AE10-4632-AD74-C177F1B1D288Q35253350-D73DF0AC-A660-434D-A46D-9C5E23151312Q35661531-711E537F-1A0C-4E16-B054-09B35DC3AB44Q35916938-1A8DC97E-14FB-4CE4-B7DC-604D44265CC1Q36551124-5C55BDF7-1C4B-4B2B-864D-EEC1535ECEC9Q37269100-B82F2C1A-C01A-4CC8-865F-A602F3B10E6BQ37363593-0869D82B-80B0-42D3-80DB-CB9C0DCE277EQ38390072-1C4CA047-B36F-43DF-9EBB-35B5510A927FQ38769177-0B00B2AD-2269-46A2-A52A-22FF1A68C3F6Q39699060-08263F60-B12A-4DB3-A1D6-9F372284DB02Q41852975-38389C92-8415-4A67-8168-6DEB618A2ECBQ47110047-F7D4167F-8C65-4904-B38B-E636B24B4C09Q55437999-194317CB-2A3C-4647-BC21-EA3E3259AAA1
P2860
Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Expression of class III beta t ...... stance to taxane chemotherapy.
@en
Expression of class III beta t ...... stance to taxane chemotherapy.
@nl
type
label
Expression of class III beta t ...... stance to taxane chemotherapy.
@en
Expression of class III beta t ...... stance to taxane chemotherapy.
@nl
prefLabel
Expression of class III beta t ...... stance to taxane chemotherapy.
@en
Expression of class III beta t ...... stance to taxane chemotherapy.
@nl
P2093
P1433
P1476
Expression of class III beta t ...... istance to taxane chemotherapy
@en
P2093
Anthony Frankfurter
Charles Dumontet
Françoise Bejui-Thivolet
Maurice Perol
Nadine Peloux
Pierre-Jean Souquet
Richard Luduena
Sylvie Isaac
Yves Pacheco
P304
P577
2005-02-01T00:00:00Z